Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329393 · ClinicalTrials.gov registry record · Phase 1
Benefits Management for People With Psychiatric Disabilities
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT01329393: Completed Phase 1 study, sponsored by Yale University.
NCT01329393 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 99 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01329393, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
This stage 1 clinical trial will determine pilot efficacy, develop a therapy manual, and collect qualitative data concerning a brief money management intervention for people disabled by psychiatric illnesses.
Primary Outcome
The Heinrich-Carpenter Quality of Life score is derived by summing ratings of individual items after a semi-structured interview. The possible score on any given interview is 0-126. It is a global measure of social functioning with higher scores indicating better functioning.
Interventions
- BEHAVIORAL Illness Management and Recovery
- BEHAVIORAL Benefits Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01329393 record still lists
NCT01329393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 2 interventions - of which Illness Management and Recovery is the first listed.
NCT01329393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01329393 about?
NCT01329393 is a clinical study titled "Benefits Management for People With Psychiatric Disabilities". This stage 1 clinical trial will determine pilot efficacy, develop a therapy manual, and collect qualitative data concerning a brief money management intervention for people disabled by psychiatric illnesses.
What is the current status of trial NCT01329393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2010-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01329393?
The interventions under investigation include: Illness Management and Recovery (BEHAVIORAL), Benefits Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT01329393?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01329393's enrollment target sits among peer trials
99 590th of 2000 higher than 1,409 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia